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Abstract:  
The main objective of present work was to develop simple spectrophotometric multicomponent method of analysis i. 
e. simultaneous equation method. Tenofovir disoproxil fumarate & Emtricitabine was first approved in US in July 
2003 and is indicated for adults aged > or =18 years. This method is used for dissolution study of Tenofovir 
disoproxil fumarate and Emtricitabine in combined tablet dosage form. As per USFDA guidelines, dissolution study 
was carried out in 900 mL 0.01 N HCl. Dissolution study was carried out using a USP Type 2 (Paddle) apparatus at 
a stirring rate of 50 rpm for 45 minutes as per USFDA guidelines. Tenofovir disoproxil fumarate and Emtricitabine 
showed 258 and 286 nm as λmax in 0.01N HCl respectively. The drug release from tablet was evaluated by developed 
spectroscopic methods i. e. simultaneous equation method. At the end of 45 minutes, % Cumulative drug release of 
Emtricitabine & Tenofovir disoproxil fumarate was found to be 104.9 & 98.8 %  based on developed method. The 
developed method was found to be simple, rapid, less tedious & economical compare to other reported methods in 
literature. The developed method can be a good alternative method for quality control testing of Emtricitabine & 
Tenofovir disoproxil fumarate in combined dosage form.   
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INTRODUCTION: 
Emtricitabine (EMT) (4-amino-5-fluoro-1-[(2S,5R)-
2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2 
dihydropyrimidin-2-one), an analogue of cytidine, 
Fig. No. 1 and Tenofovir disoproxil fumarate (TDF) 
(({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-
yl]oxy}methyl)phosphonic acid), are nucleoside 
reverse transcriptase inhibitor (NRTI) that are used 
for the treatment of HIV infection fig. no. 2 [1] 
TDF is a bioavailable prodrug of Tenofovir, a potent 
nucleotide analogue reverse-transcriptase inhibitor 
with activity against human immunodeficiency virus 
(HIV) and hepatitis B virus [2]. 
 
Fig.1: Chemical Structure of Emtricitabine 
 
Fig.2: Chemical Structure of Tenofovir disoproxil 
fumarate 
Drug dissolution (or release) testing is an analytical 
technique used to assess release profiles of drugs in 
pharmaceutical products, generally for solid oral 
products such as tablets and capsules[3]. Dissolution 
test gains its significance from the fact that if a drug 
from a product is to produce its effect; it must be 
released from the product and should generally be 
dissolved in the fluids of the gastrointestinal (GI) 
tract from which it will subsequently gets absorb 
easily. Thus, a drug dissolution test may be 
considered as an indicator of potential drug release 
and absorption characteristics of a product in humans 
as well as in animals. Therefore, a dissolution test is 
often considered a surrogate for the assessment of 
availability of drugs in the body, generally termed 
bioavailability[4].  
The TDF and EMT combined tablet is official in 
Indian pharmacopoeia 2010. The method given for 
dissolution is by High Performance Liquid 
Chromatography (HPLC) which is tedious, costly and 
time consuming [5]. A literature survey revealed that 
HPLC[6], spectrophotometric techniques by 
simultaneous[7]& Area Under Curve [8]& High 
Performance Thin Layer Chromatography 
(HPTLC)[9] have been reported for the simultaneous 
determination of EMT, and TDF in pure drug, 
pharmaceutical dosage forms and biological samples.  
The reported methods are quite tedious, time 
consuming & complicated. Hence, the authors have 
attempted to develop a simple method for the 
simultaneous estimation of these drugs in tablet 
dosage forms and its application for dissolution study.  
 
MATERIAL AND METHODS: 
Chemicals and Reagents: 
Pharmaceutical grade of Emtricitabine and Tenofovir 
disproxil fumarate were kindly supplied as gift 
sample by Lupin Pharmaceuticals Ltd. All the 
chemicals were used of analytical grades. The 
marketed formulations were purchased from local 
market were obtained from retail pharmacist.  
 
Instruments: 
UV-Visible Spectrophotometer (Agilent-Cary 60) 
with cuvette cells of 1 cm light path was used for the 
measurement of absorbance. The USP dissolution 
apparatus (Electrolab ETC-11L) was used for 
dissolution study. Electronic Balance (Schimadzu 
BL-220H) was used for weighing the samples. Class 
‘A’ volumetric glassware’s were used. Ultra-
Sonicator (Wensar-WUC-2L) was used for sonication 
purpose. 
 
Procedure: 
Selection of Dissolution Medium: 
The solvent i.e. 0.01N HCl was selected as 
Dissolution medium for estimation of Emtricitabine 
and Tenofovir Disproxil fumarate in tablet dosage 
form as per US FDA guidelines (USFDA 2007). 
 
Preparation of standard stock solution: 
An accurately weighed quantity of about 20 mg 
Emtricitabine and Tenofovir Disproxil fumarate was 
taken in a 100 mL volumetric flask and was dissolved 
in 0.01N HCl with sonication. The volume was made 
up to mark with Solvent to get the concentration of 
200 ppm. 
 
 
IAJPS 2017, 4 (10), 3650-3654                    Rajendra Mogal et al                     ISSN 2349-7750 
 w w w . i a j p s . c o m  
 
Page 3652 
Preparation of Working Standard Solution of 
Emtricitabine and Tenofovir Disproxil fumarate: 
The aliquot portion of standard stock solution of 
Emtricitabine and Tenofovir Disproxil fumarate was 
diluted appropriately with 0.01N HCl obtaining 
concentration 10 μg/mL. Solutions were taken in 1 
cm cell and scanned in the range 200 nm to 400 nm 
and spectrum were recorded as showed in Fig. 3 & 
Fig. 4 for EMT & TDF respectively. 
 
Fig. 3: UV spectra of Emtricitabine in 0.01 N HCl 
 
Fig. 4: UV spectra of Tenofovir disoproxil fumarate in 0.01 N HCl 
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Method I: Simultaneous equation method 
From the spectra of pure drugs, two wavelengths, 258 
nm (λmax of TDF) and 286 nm (λmax of EMT) were 
selected for the formation of simultaneous equation. 
The A (1%, 1 cm) was determined at both the 
wavelengths selected for each drug. Samples 
containing two absorbing species EMT and TDF (X 
& Y) & both absorbs at the λmax of the other. So the 
absorbance of each drug at both wavelengths λ1 & λ2 
were measured respectively. Both the drugs were 
determined by simultaneous method (Vierodt’s 
method). The absorptivity of EMT (X) at λ1 (286) 
and λ2 (258) is ax1 and ax2, respectively. The 
absorptivity of TDF (Y) at λ1 (286) and λ2 (258) is 
ay1 and ay2, respectively [10]. 
The absorptivity of each solution was calculated by 
using the following formula: 
Absorptivity = Absorbance / 
concentration (g/100 mL) 
The absorbance of the sample (formulation) at λ1 
(286) and λ2 (258) is A1 and A2 respectively.  
The total absorbance of the mixture is equal to the 
sum of individual absorbance of X and Y.  
A1 = ax1bCx + ay1bCy --------- (1) 
A2 = ax2bCx + ay2bCy ---------- (2) 
Cx= A2ay1-A1ay2/ ax2 ay1- ax1 ay2 ------------ (3) 
Cy= A1ax2-A2ax1/ ax2 ay1- ax1 ay2 ------------- (4) 
Cx: Concentration of EMT 
Cy: Concentration of TDF  
Dissolution study: 
Dissolution testing was carried out using paddle (USP 
Apparatus 2) at 50 rpm using 900 mL of 0.01 N HCl 
as dissolution medium for 45 min at 37 ± 0.5 0C. 5.0 
mL sample aliquots were withdrawn at intervals of 5, 
10, 15, 30, and 45 min and replaced with an equal 
volume of the fresh medium to maintain sink 
condition. After the end of each test time, sample 
aliquots were filtered, diluted with 0.01N HCl and 
quantified. The analysis of dissolution samples was 
performed using simultaneous equation method. The 
proposed method was employed to calculate the 
percentage release at respective time interval of 
dissolution profile. The dissolution parameters set is 
as per table no. 1.[11,12] 
Table No. 1: Dissolution parameters for Emtricitabine 
and Tenofovie disoproxil fumarate 
Dissolution parameters  
Dissolution apparatus USP apparatus II (Paddle) 
Dissolution medium 0.01N HCl 
Volume of dissolution 
medium (mL) 
900 
Speed of paddle rotation 
(rpm) 
50 
Temperature (0C) 37 ± 0.5 
Sampling time (minutes) 5, 10, 15, 20, 30, & 45 
 
RESULT AND DISCUSSION: 
Simultaneous equation: 
Two wavelengths, 258 nm (λmax of TDF) and 286nm 
(λmax of EMT) were found in 0.01N HCl as per 
spectral analysis. The absorptivity of EMT (X) at λ1 
and λ2 is ax1 (130.85) and ax2 (361.70) respectively. 
The absorptivity of TDF (Y) at λ1 and λ2 is ay1 
(230.25) and ay2 (18.25) respectively. After solving 
equation no. 3 & 4, the concentrations of EMT & 
TDF were calculated. 
Dissolution study 
The dissolution study was carried out using 0.01N 
HCl as dissolution medium at stated conditions. The 
absorbance at different time points were measured & 
respective concentrations of EMT and TDF were 
calculated by simultaneous equation method. After 
that % CDR for both drugs were calculated & 
obtained results shown in Table no. 2.  
 
Table 2: % CDR at different time points 
 
Time Points (Min) % CDR of Emtricitabine % CDR of Tenofovir disoproxil Fumarate 
5 56.16 51.92 
10 88.82 82.49 
15 96.05 92.3 
30 102.05 92.83 
45 104.9 98.8 
The graph of % CDR against Time point was plotted as shown in Fig. no. 5. At the end of 45 min, 104.9 EMT & 
98.8 TDF percent drug release was found. 
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Fig.5: A plot of % CDR against time points (Dissolution Profile) for Emtricitabine & Tenofovir Disoproxil 
Fumarate 
CONCLUSION: 
The developed method offers numerous advantages 
over chromatographic (HPLC) analysis like 
comparatively simple, rapid, reproducible, less time 
consuming, & economical method for simultaneous 
estimation of Emitricitabine and Tenofovir disoproxil 
fumarate. Hence the proposed method can be used for 
routine analysis of both the drugs in combined 
dosage form. The method could be satisfactorily 
employed in dissolution studies to determine the 
percentage drug release. 
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